Alkem Sees Domestic Recovery And International Growth

As Company Receives 10 ANDA Approvals In Financial Third Quarter

India’s Alkem has announced growing domestically in its financial third quarter, after seeing a low first quarter due to COVID-19. The company has also reported progress in the international market, after receiving 10 ANDA approvals from the US FDA in Q3 FY21.

Indian Flag
Alkem features amongst the top five companies in the Indian pharmaceutical market • Source: Shutterstock

After seeing a drop in its domestic business in the first quarter of FY21, India’s Alkem Laboratories Ltd has announced growth of 6.3% in Indian sales to INR15.1bn ($207m) in its financial third quarter ended 31 December 2020. For the first nine months of FY21, the company's domestic sales were INR42.3bn compared to INR42.0bn reported in the corresponding prior year period.

Alkem managing director Sandeep Singh commented, “Over the last two quarters, our India business has shown a significant recovery from...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business